InvaGen Pharmaceuticals Facility Expansion Completed
June 6, 2024

InvaGen Pharmaceuticals Facility Expansion Completed

Dacon Corporation has completed an expansion to InvaGen Pharmaceuticals’ Fall River manufacturing facility. InvaGen is a subsidiary of Cipla (Chemical Industrial Pharmaceutical Laboratories), a global firm founded in 1935 by Dr. K.A. Hamied, who was inspired by Mahatma Gandhi to make India self-sufficient in healthcare. Most notably, Cipla manufactured the first respiratory inhalers in India, followed by the landmark creation of the first triple HIV cocktail therapy for Doctors without Borders. This reduced AIDS treatment to $1 per day, enabling accessible therapies to underserved populations. Today Cipla’s mission of affordable, high-quality medicines spans a continuum of therapeutic categories. Centered on ‘Caring for Life’, their portfolio encompasses over 1,500 products in 86 countries.  

Acquired in 2016 as part of a global initiative, the InvaGen Pharmaceuticals division is responsible for the research, development and manufacturing of vital respiratory medications for pediatric and adult use. This facility expansion is in response to employee and manufacturing growth. The need for accessibility, affordability, and efficiency continues to rise for respiratory medications.  Fueled by the growth of asthma, COPD and bronchitis, the inhaler market was valued at $4.6B in 2022 and is anticipated to grow to $8B by 2030[1].  

[1] Global Albuterol Market – Industry Trends and Forecast to 2030, Data Bridge Market Research,,indicates%20that%20the%20market%20value.  


More Insights and Resources

June 21, 2024

Dacon Corp. Completes InvaGen Pharmaceuticals’ Manufacturing Facility

View more
June 10, 2024

Dacon Completes InvaGen Pharmaceuticals Facility Expansion

View more
April 26, 2024

Camber Development and Dacon Commence 238,000 s/f Industrial Distribution Facility; Event Marked with Build-a-Bureau Program

View more

Intelligence by design

Sign up here to receive MATTER, our quarterly design build insights publication, by email.​​​